{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Lutetium_Lu_177-Edotreotide",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A radioconjugate consisting of the somatostatin analogue edotreotide labeled with lutetium Lu 177 with potential antineoplastic activities. Lutetium Lu 177-edotreotide binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide (Tyr3-octreotide or TOC) and chelated by the bifunctional, macrocyclic chelating agent dodecanetetraacetic acid (DOTA).",
    "fdaUniiCode": "RGO812Q0C8",
    "identifier": "C88277",
    "preferredName": "Lutetium Lu 177-Edotreotide",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129819",
      "C2124"
    ],
    "synonyms": [
      "177Lu-DOTATOC",
      "177Lu-Edo",
      "177Lu-Edotreotide",
      "EDOTREOTIDE LUTETIUM LU-177",
      "Lutetium 177Lu-Edotreotide",
      "Lutetium Lu 177 DOTA-Tyr3-octreotide",
      "Lutetium Lu 177-Edotreotide",
      "[177LuDOTA]-TOC"
    ]
  }
}